Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
Fundazion Italiana delle sindromi mielodisplastiche, Florence, Italy.
Valeria
V
Santini
Jennifer
J
Schemenau
Alessandro
A
Levis
Enrico
E
Balleari
Rosa
R
Sapena
Lionel
L
Adès
Agnès
A
Guerci
Odile
O
Beyne-Rauzy
Marie-Pierre
MP
Gourin
Stephane
S
Cheze
Aspasia
A
Stamatoullas
Alessandro
A
Sanna
Daniela
D
Gioia
Gianni
G
Cametti
Dario
D
Ferrero
Emmanuel
E
Raffoux
Christian
C
Rose
Antonella
A
Poloni
Thomas
T
Prebet
Laurence
L
Legros
Shanti
S
Natarajan-Amé
Pierre
P
Fenaux
Ulrich
U
Germing
François
F
Dreyfus
Sophie
S
Park
D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D011379:Prognosis; D012189:Retrospective Studies; D012720:Severity of Illness Index
D006397:Hematinics